Recombinant protein and its construction method and use
A technology of recombinant protein and fibronectin, which is applied in the field of recombinant protein, can solve the problems of poor transdermal performance of protein-polypeptide complexes, poor stability of fibronectin, and restrictions on the application of protein polypeptides, so as to improve transdermal properties, Low cost, easy preparation and low effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0040] The research and development of embodiment 1 transdermal fibronectin mutant
[0041] 1. Mutant research and development ideas:
[0042] There are surfactants, thickeners, essences, polyols and other ingredients in cosmetic formulations, which will affect the stability of protein peptides in cosmetics. At the same time, cosmetics may encounter high temperature conditions during transportation and storage, which will accelerate the degradation of protein peptides.
[0043] In the present invention, the transdermal peptide and fibronectin are recombined, the sequence of the recombinant transdermal fibronectin is shown in SEQ ID No.6, and then according to the three-dimensional structural characteristics of the recombinant transdermal fibronectin, amino acid point mutations are carried out on the surface of the recombinant transdermal fibronectin, It can significantly improve the stability of recombinant transdermal fibronectin. The selection of mutation points should not ...
Embodiment 2
[0050] Example 2 Construction of Transdermal Fibronectin Mutant Recombinant Protein Particles
[0051] In the embodiment of the present invention, the amino acid sequence of the recombinant transdermal fibronectin mutant (A-7) is shown in SEQ ID No.1, and the gene sequence encoding SEQ ID No.1 is shown in SEQ ID No.2.
[0052] Build method:
[0053] (1) According to the position design of the relevant sequence of the commercial vector pPICZaA, the enzyme cutting sites EcoR I and SalI were selected; the DNA sequence encoding the transdermal fibronectin mutant recombinant protein is shown in SEQ ID No.2;
[0054] (2) There is a restriction endonuclease site at the 5' and 3' ends of the synthetic recombinant protein DNA sequence, corresponding to EcoR I and SalI respectively;
[0055] (3) Insert the target fragment of the recombinant protein into the restriction site of the vector to obtain the expression plasmid encoding the above recombinant protein. The structure of the vecto...
Embodiment 3
[0056] Example 3 Construction of Transdermal Fibronectin Mutant-Elastase Inhibiting Peptide Recombinant Protein Particles
[0057] In the embodiment of the present invention, the transdermal fibronectin mutant-elastase inhibitory peptide recombinant protein is the flexible end of the recombinant transdermal fibronectin mutant prepared in Example 2 connected to the elastase inhibitory peptide through a connecting peptide, the recombinant protein The amino acid sequence of is shown in SEQ ID No.4.
[0058] Build method:
[0059] (1) According to the position design of the relevant sequence of the commercial vector pPICZaA, the enzyme cleavage sites EcoR I and SalI were selected; the DNA sequence encoding the transdermal fibronectin mutant-elastase inhibitory peptide recombinant protein is shown in SEQ ID No.5;
[0060] (2) There is a restriction endonuclease site at the 5' and 3' ends of the synthetic recombinant protein DNA sequence, corresponding to EcoR I and SalI respective...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


